225 related articles for article (PubMed ID: 34097520)
1. Biosimilars And Follow-On Products In The United States: Adoption, Prices, And Users.
Stern AD; Chen JL; Ouellet M; Trusheim MR; El-Kilani Z; Jessup A; Berndt ER
Health Aff (Millwood); 2021 Jun; 40(6):989-999. PubMed ID: 34097520
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
Lee HJ; Han E; Kim H
Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
[TBL] [Abstract][Full Text] [Related]
3. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
[TBL] [Abstract][Full Text] [Related]
4. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
5. Optimizing use and addressing challenges to uptake of biosimilars.
Leber MB
Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars in Oncology in the United States: A Review.
Nabhan C; Parsad S; Mato AR; Feinberg BA
JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
Falit BP; Singh SC; Brennan TA
Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
[TBL] [Abstract][Full Text] [Related]
8. Cancer Drug Trastuzumab And Its Biosimilars Compete On Price For Market Share.
Chen AJ; Kaiser KM; Gascue L; Manetas MA; Van Nuys K
Health Aff (Millwood); 2023 Jun; 42(6):779-784. PubMed ID: 37276475
[TBL] [Abstract][Full Text] [Related]
9. The Inflation Reduction Act: A boon for the generic and biosimilar industry.
Niazi SK
J Clin Pharm Ther; 2022 Nov; 47(11):1738-1751. PubMed ID: 36207987
[TBL] [Abstract][Full Text] [Related]
10. Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.
Wouters OJ; Kanavos PG; McKEE M
Milbank Q; 2017 Sep; 95(3):554-601. PubMed ID: 28895227
[TBL] [Abstract][Full Text] [Related]
11. Projected US savings from biosimilars, 2021-2025.
Mulcahy A; Buttorff C; Finegold K; El-Kilani Z; Oliver JF; Murphy S; Jessup A
Am J Manag Care; 2022 Jul; 28(7):329-335. PubMed ID: 35852882
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland.
Carl DL; Laube Y; Serra-Burriel M; Naci H; Ludwig WD; Vokinger KN
JAMA Netw Open; 2022 Dec; 5(12):e2244670. PubMed ID: 36459139
[TBL] [Abstract][Full Text] [Related]
13. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
Grabowski HG; Guha R; Salgado M
Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars: How Can Payers Get Long-Term Savings?
Mestre-Ferrandiz J; Towse A; Berdud M
Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
[TBL] [Abstract][Full Text] [Related]
15. Biologic Drugs, Biosimilars, and Barriers to Entry.
Shepherd JM
Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844
[TBL] [Abstract][Full Text] [Related]
16. Overview of biosimilars for immune-mediated inflammatory diseases: summary of current evidence.
Strand V; Evans C; Gibofsky A
Am J Manag Care; 2022 Nov; 28(12 Suppl):S217-S226. PubMed ID: 36493395
[TBL] [Abstract][Full Text] [Related]
17. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
Hair J; Maryon T; Lieneck C
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
[TBL] [Abstract][Full Text] [Related]
18. Are There Benefits and Risks to Biosimilars from a Patient Perspective?
Kay J
Rheum Dis Clin North Am; 2019 Aug; 45(3):465-476. PubMed ID: 31277756
[TBL] [Abstract][Full Text] [Related]
19. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
20. [Can we transfer the mechanisms of the generics market to biosimilars?].
Jacke CO; Wild F
Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
